GFAp与tau蛋白作为院外心脏骤停后神经功能结局预测因素:COMACARE试验的事后分析
该研究为COMACARE试验(NCT02698917)的事后分析,纳入112例院外心脏骤停(OHCA)患者,在入ICU时及OHCA后24、48、72小时测定血浆GFAp与tau蛋白浓度,并与NSE比较,以6个月时CPC评分3-5分定义为不良结局。39/112(35%)患者出现不良结局。48小时GFAp中位数在不良组为1514(886-4995)pg/ml,优于良好组的238(135-463)pg/ml(p<0.001);tau分别为99.6(14.5-352)与3.0(2.2-4.8)pg/ml(p<0.001)。48和72小时GFAp的AUROC为0.91(0.85-0.97)和0.91(0.85-0.96),tau为0.93(0.86-0.99)和0.95(0.89-1.00),NSE为0.86(0.79-0.94)和0.90(0.82-0.97),GFAp或tau与NSE的预测准确性差异无统计学意义。
要点
- OHCA后48小时,不良结局组GFAp中位数1514(886-4995)pg/ml,显著高于良好结局组的238(135-463)pg/ml(p<0.001)。
- OHCA后48小时,不良结局组tau中位数99.6(14.5-352)pg/ml,显著高于良好结局组的3.0(2.2-4.8)pg/ml(p<0.001)。
- 48和72小时GFAp预测6个月不良结局的AUROC分别为0.91(0.85-0.97)和0.91(0.85-0.96)。
- 48和72小时tau的AUROC分别为0.93(0.86-0.99)和0.95(0.89-1.00),NSE分别为0.86(0.79-0.94)和0.90(0.82-0.97)。
- GFAp或tau与NSE的预测准确性差异无统计学意义,两者均不优于NSE。
适用人群与场景
- 纳入COMACARE试验的院外心脏骤停(OHCA)患者,共112例。
- 在ICU入院时及OHCA后24、48、72小时测量血浆GFAp和tau浓度。
诊断标准与关键阈值
- 不良结局定义为OHCA后6个月脑功能分类(CPC)评分3-5分。
研究设计与关键结果
- 研究类型为COMACARE试验(NCT02698917)的事后分析,共纳入112例OHCA患者。
- 39/112(35%)患者出现不良结局(6个月CPC评分3-5分)。
- 随时间推移,不良结局组的GFAp和tau浓度均显著高于良好结局组(p<0.001)。
- 48小时GFAp中位数(四分位距)在不良结局组为1514(886-4995)pg/ml,良好结局组为238(135-463)pg/ml(p<0.001)。
- 48小时tau中位数(四分位距)在不良结局组为99.6(14.5-352)pg/ml,良好结局组为3.0(2.2-4.8)pg/ml(p<0.001)。
- 48和72小时GFAp的AUROC分别为0.91(95%CI 0.85-0.97)和0.91(95%CI 0.85-0.96)。
- 48和72小时tau的AUROC分别为0.93(95%CI 0.86-0.99)和0.95(95%CI 0.89-1.00)。
- 48和72小时NSE的AUROC分别为0.86(95%CI 0.79-0.94)和0.90(95%CI 0.82-0.97)。
证据类型、等级与局限
- 证据类型:COMACARE试验(NCT02698917)的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,OHCA后48和72小时血清GFAp和tau均表现出预测结局的优秀准确性,但不优于NSE。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To determine the ability of serum glial fibrillary acidic protein (GFAp) and tau protein to predict neurological outcome after out-of-hospital cardiac arrest (OHCA).
METHODS: We measured plasma concentrations of GFAp and tau of patients included in the previously published COMACARE trial (NCT02698917) on intensive care unit admission and at 24, 48, and 72 h after OHCA, and compared them to neuron specific enolase (NSE). NSE concentrations were determined already during the original trial. We defined unfavourable outcome as a cerebral performance category (CPC) score of 3-5 six months after OHCA. We determined the prognostic accuracy of GFAp and tau using the receiver operating characteristic curve and area under the curve (AUROC).
RESULTS: Overall, 39/112 (35%) patients had unfavourable outcomes. Over time, both markers were evidently higher in the unfavourable outcome group (p < 0.001). At 48 h, the median (interquartile range) GFAp concentration was 1514 (886-4995) in the unfavourable versus 238 (135-463) pg/ml in the favourable outcome group (p < 0.001). The corresponding tau concentrations were 99.6 (14.5-352) and 3.0 (2.2-4.8) pg/ml (p < 0.001). AUROCs at 48 and 72 h were 0.91 (95% confidence interval 0.85-0.97) and 0.91 (0.85-0.96) for GFAp and 0.93 (0.86-0.99) and 0.95 (0.89-1.00) for tau. Corresponding AUROCs for NSE were 0.86 (0.79-0.94) and 0.90 (0.82-0.97). The difference between the prognostic accuracies of GFAp or tau and NSE were not statistically significant.
CONCLUSIONS: At 48 and 72 h, serum both GFAp and tau demonstrated excellent accuracy in predicting outcomes after OHCA but were not superior to NSE.
CLINICAL TRIAL REGISTRATION: NCT02698917 (https://www.clinicaltrials.gov/ct2/show/NCT02698917).
参考来源
- Humaloja J, Lähde M, Ashton NJ, et al. GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. Resuscitation. 2021. PMID: 34863908. doi:10.1016/j.resuscitation.2021.11.033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。